Ok stk number two and I think I'm going to let it go after this.... GLUU mobile is right on the cusp... but we all know about HOLX spending is down at hospitals and digital mammograms are slowing assimilation problems with big purchase pap smears not what they used to be etc.... what it all adds up to is a great growth stk on sale. Twice before I remembeber big 25% clips and the stk went on to new highs and splits.... will it happen again.... ? HOLX POSTS $0.22 Q2 EPS. OPPENHEIMER SAYS SELL-OFF OVERDONEFont size: A | A | A undefined undefined | S&P Marketscope RELATED QUOTES 9:43 AM ET 5/14/08 Symbol Last % Chg HOLX 21.65 0.32% Real time quote. SNPMarketScopeViewsNews2008-05-01 14:37:16.000HOLXHOLOGIC, INC.Barney BrodieHOLX POSTS $0.22 Q2 EPS. OPPENHEIMER SAYS SELL-OFF OVERDONEAnalyst Amit Hazan believes HOLX stock's sell-off overdone, he would be buyer. Says key focus for investors heading into Q2 was Selenia, which beat expectations on both orders and installs once again. Key concerns, as he sees them now, are NovaSure weakness, Pap volume, gross margin. Notes while he's clearly concerned with rate of slowdown in Nova biz, even flat growth in it for next two years would only impact his EPS estimate by less than $0.05. Says Nova comprises only 13% of $1.7B in sales expected for FY 08 (Sep). Says gross margin was not stronger in Q2 because of NovaSure; Pap biz remains stable. Maintains outperform, has $39.50 and... Recommendations story about HOLX from Citigroup Citigroup believes the upcoming Tomosynthesis approval in the second half of 2008 is a meaningful positive catalyst and reiterates a Buy rating on the stock.